Sporanox to be avoided in heart failure

The antifungal agent Sporanox (itraconazole) should not be used in patients with congestive heart failure or a history of congestive heart failure unless the benefit clearly outweighs the risk.

The warning follows observations that Sporanox exerts a negative inotropic effect, and reports of congestive heart failure associated with its use.

If the benefits do exceed the risk of using Sporanox in patients with heart failure, such patients should be monitored closely and the drug discontinued if symptoms of heart failure develop.

View Sporanox drug record

Further Information: Janssen-Cilag Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Third tiotropium inhaler adds to treatment options for COPD patients

Third tiotropium inhaler adds to treatment options for COPD patients

Tiogiva is a new breath-actuated inhaler containing...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...